article · Journal of Complementary and Integrative Medicine
Abstract Objectives Due to the widespread and extensive use of the endocrine disruptor bisphenol A (BPA) in our daily life, several studies were performed to attenuate its adverse effects. Thus, taurine was used in the current study to evaluate its protective action against BPA cardiotoxic effects. Methods Rats were divided into control rats, BPA-intoxicated rats, and BPA-intoxicated rats treated with taurine. After six weeks of daily oral BPA treatment (25 mg/kg), the cardio-protective effect of taurine (100 mg/kg) was determined by the measurement of the serum activities of lactate dehydrogenase (LDH) and creatine kinase-MB (CK-MB) and the levels of Wnt, β-catenin, lipid peroxidation (MDA), nitric oxide (NO), reduced glutathione (GSH) and Na + , K + , ATPase activity in the myocardium. Additionally, the effects of taurine on the cardiac histopathological alterations caused by BPA were evaluated. Results BPA-treated animals exhibited significantly elevated levels of MDA (4.7 ± 0.4 vs. 3.2 ± 0.2), Wnt (4.3 ± 0.3 vs. 2.9 ± 0.1), β-catenin (781.4 ± 37.9 vs. 599.1 ± 43.2), and increased serum activities of LDH (957.9 ± 78.6 vs. 662.3 ± 30.2) and CK-MB (347.3 ± 32.1 vs. 74.9 ± 15.2). In addition, BPA significantly decreased myocardial levels of GSH (4.6 ± 0.2 vs. 5.7 ± 0.2) and NO (0.2 ± 0.01 vs. 0.2 ± 0.01) levels, and Na + , K + -ATPase (1.2 ± 0.1 vs. 1.5 ± 0.1) activity. Histopathological examination showed myocardial striations, pyknosis, congestion and dilation of blood vessels. Taurine protection alleviates BPA-induced changes in MDA, NO, GSH, Na + , K + , ATPase, LDH, CK-MB, and Wnt restoring them to control-like values. However, β-catenin level was increased in taurine-rats. Taurine also improved the histopathological changes caused by BPA. Accordingly, taurine could potentially impose cardio-protection against BPA cardiotoxicity in male rats.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1515/jcim-2025-0446
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.